This aspect enabled us to evaluate CLL cell mobilization induced by specific drugs (in this case we used the BTK inhibitor ibrutinib), which is not possible in conventional 2D culture settings. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.